Dyspepsia Management in Primary Care

Scandinavian Journal of Gastroenterology, Supplement

Volumn 38, Issue 239, 2003, Pages 44-50

  Thijs, J C ^a   Arents, N L A ^b   Van Zwet, A A ^b   Kleibeuker, J H ^b  

^a Bethesda Hospital   (Netherlands)

^b NONE

Author keywords

Dyspepsia; H. pylori; Patient management; Test and treat

Indexed keywords

ANTIBIOTIC AGENT; CLARITHROMYCIN; HISTAMINE H2 RECEPTOR ANTAGONIST; METRONIDAZOLE; STOMACH SECRETION INHIBITOR; ANTIULCER AGENT; DIAGNOSTIC AGENT; ENZYME INHIBITOR; UREA;

BIOPSY; CLINICAL TRIAL; CONFERENCE PAPER; DYSPEPSIA; EMPIRICISM; ENDOSCOPY; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; POPULATION RESEARCH; PREDICTION; PREVALENCE; PRIORITY JOURNAL; SYMPTOMATOLOGY; BREATH ANALYSIS; DIGESTIVE TRACT ENDOSCOPY; METHODOLOGY; PRIMARY HEALTH CARE; REVIEW;

ANTI-ULCER AGENTS; BREATH TESTS; DYSPEPSIA; ENDOSCOPY, DIGESTIVE SYSTEM; ENZYME INHIBITORS; HELICOBACTER INFECTIONS; HUMANS; PRIMARY HEALTH CARE; UREA;

EID: 1642497611     PISSN: 00855928     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (65)

1. Talley NJ, Stanghellini V, Heading RC, Koch KL, Malagelada JR, Tytgat GN. Functional gastroduodenal disorders. Gut 1999;45 Suppl 2:II37-II42.
2. Veldhuyzen van Zanten SJ, Flook N, Chiba N, Armstrong D, Barkun A, Bradette M, et al. An evidence-based approach to the management of uninvestigated dyspepsia in the era of Helicobacter pylori, Canadian Dyspepsia Working Group., Can Med Assoc J 2000;162 Suppl 12:S3-23.
3. Jones R, Lydeard S. Prevalence of symptoms of dyspepsia in the community. Br Med J 1989;298:30-2.
4. Talley NJ, Zinsmeister AR, Schleck CD, Melton LJ. Dyspepsia and dyspepsia subgroups: a population-based study. Gastroenterology 1992;102:1259-68.
5. Talley NJ. Dyspepsia management in the millennium: the death of test and treat? [editorial] Gastroenterology 2002;122:1521-5.
6. Ofman JJ, Rabeneck L. The effectiveness of endoscopy in the management of dyspepsia: a qualitative systematic review. Am J Med 1999;106:335-46.
7. American College of Physicians., Endoscopy in the evaluation of dyspepsia. Ann Intern Med 1985;102:266-9.
8. Chiba N, Bernard L, O'Brien BJ, Goeree R, Hunt RH. Canadian physician survey of dyspepsia management. Can J Gastroenterol 1998;12:83-90.
9. Numans ME, de Wit NJ, Geerdes RHM, Muris JWM, Starmans R, Postema PJ, et al. NHG-standaard maagklachten (eerste herziening). Huisarts en Wetenschap 1996;39:565-77.
10. Arents NLA, Thijs JC, Kleibeuker JH. A rational approach to uninvestigated dyspepsia in primary care. Review of the literature. Postgraduate Med J 2002;78:707-16.
11. Graham DY, Colon-Pagan J, Morse RS, Johnson TL, Walsh JH, McCullough AJ, et al. Ulcer recurrence following duodenal ulcer healing with omeprazole, ranitidine, or placebo: a double-blind, multicenter, 6-month study. The Omeprazole Duodenal Ulcer Study Group. Gastroenterology 1992;102:1289-94.
12. Hetzel DJ, Dent J, Reed WD, Narielvala FM, Mackinnon M, McCarthy JH, et al. Healing and relapse of severe peptic esophagitis after treatment with omeprazole. Gastroenterology 1988;95:903-12.
13. Jones R, Lydeard S. Dyspepsia in the community: a follow-up study. Br J Clin Pract 1992;46:95-7.
14. Talley NJ. Drug treatment of functional dyspepsia. Scand J Gastroenterol 1991;182:47-60.
15. Talley NJ, Meineche-Schmidt V. Paré P, Duckworth M, Räisänen P, Pap A, et al. Efficacy of omeprazole in functional dyspepsia: double-blind, randomized, placebo-controlled trials (the Bond and Opera studies). Aliment Pharmacol Ther 1998;12:1055-65.
16. 2-blocker therapy or prompt endoscopy in management of dyspepsia. Lancet 1994;343:811-6.
17. Kuipers EJ, Thijs JC, Festen HPM. Helicobacter pylori and peptic ulcer disease. Aliment Pharmacol Ther 1995;9Suppl 2:59-69.
18. EUROGAST study group., An international association between Helicobacter pylori infection and gastric cancer. Lancet 1993;341:1359-62.
19. Uemura N, Okamoto S, Yamamoto S, Matsamura N, Yamaguchi S, Yamakido M, et al. Helicobacter pylori infection and the development of gastric cancer. N Engl J Med 2001;345:784-9.
20. Moayyedi P, Soo S, Deeks J, Forman D, Mason J, Innes M, et al. Systematic review and economic evaluation of Helicobacter pylori eradication treatment for non-ulcer dyspepsia. Br Med J 2000;321:659-64.
21. Laine L, Schoenfeld P, Fennerty MB. Therapy for Helicobacter pylori in patients with nonulcer dyspepsia. A meta-analysis of randomized, controlled trials. Ann Intern Med 2001;134:361-9.
22. The European Helicobacter pylori Study Group, Current European concepts in the management of H. pylori infection. The Maastricht consensus report. Gut 1997;41:8-13.
23. Talley NJ, Siverstein MD, Agreus L, Nyren O, Sonnenberg A, Holtman G. AGA technical review: evaluation of dyspepsia. American Gastroenterological Association. Gastroenterology 1998;114:582-95.
24. Lam SK, Talley NJ. Report of the 1997 Asia Pacific Consensus Conference on the management of Helicobacter pylori infection. J Gastroenterol Hepatol 1998;13:1-12.
25. Talley NJ, Axon A, Bytzer P, Holtman G, Lam SK, Van Zanten S. Management of uninvestigated and functional dyspepsia: a Working Party report for the World Congresses of Gastroenterology 1998. Aliment Pharmacol Ther 1999;13:1-12.
26. Sobala GM, Crabtree JE, Pentith JA, Rathbone BJ, Shallcross TM, Wyatt JI, et al. Screening dyspepsia by serology to Helicobacter pylori. Lancet 1991;338:94-6.
27. Tham TC, McLaughlin N, Hughes DF, Ferguson M, Crosbie JJ, Madden M, et al. Possible role of Helicobacter pylori serology in reducing endoscopy workload. Postgrad Med J 1994;70:809-12.
28. Patel P, Khulusi S, Mendall MA, Lloyd R, Jazrawi R, Maxwell JD, et al. Prospective screening of dyspeptic patients by Helicobacter pylori serology. Lancet 1995;346:1315-8.
29. Fendrick AM, Chernew ME, Hirth RA, Bloom BS. Alternative management strategies for patients with suspected peptic ulcer disease. Ann Intern Med 1995;123:260-8.
30. Silverstein MD, Petterson T, Talley NJ. Initial endoscopy or empirical therapy with or without testing for Helicobacter pylori for dyspepsia: a decision analysis. Gastroenterology 1996;110:72-83.
31. Briggs AH, Sculpher MJ, Logan RP, Aldous J, Ramsay ME, Baron JH. Cost effectiveness of screening for and eradication of Helicobacter pylori in management of dyspeptic patients under 45 years of age. Br Med J 1996;312:1321-5.
32. Ofman JJ, Etchason J, Fullerton S, Kahn KL, Soll AH. Management strategies for Helicobacter pylori-seropositive patients with dyspepsia: clinical and economic consequences. Ann Intern Med 1997;126:280-91.
33. Lassen AT, Pedersen FM, Bytzer P, Schaffalitzky de Muckadell OB. Helicobacter pylori test-and-eradicate versus prompt endoscopy for management of dyspeptic patients: a randomised trial. Lancet 2000;356:455-60.
34. McColl KEL, Murray LS, Gillen D, Walker A, Wirz A, Fletcher J, et al. Randomised trial of endoscopy with testing for Helicobacter pylori compared with non-invasive H. pylori testing alone in the management of dyspepsia. Br Med J 2002;324:999-1002.
35. Arents NLA, Thijs JC, Zwet van AA, Oudkerk Pool M, Götz JM, Van de Werf GTh, et al. The approach of dyspepsia in primary care. A randomised trial comparing "test-and-treat" with prompt endoscopy. Arch Intern Med 2003;163:1606-12.
36. Heaney A, Collins JSA, Watson RGP, McFarland RJ, Bamford KB, Tham TCK. A prospective randomised trial of a test-and-treat policy versus endoscopy based management in young Helicobacter pylori positive patients with ulcer-like dyspepsia, referred to a hospital clinic. Gut 1999;45:186-90.
37. Jones R, Tait C, Sladen G, Weston-Baker J. A trial of a test-and-treat strategy for Helicobacter pylori positive dyspeptic patients in general practice. Int J Clin Pract 1999;53:413-6.
38. Christie J, Sheperd NA, Codling BW, Valori RM. Gastric cancer below the age of 55: implications for screening patients with uncomplicated dyspepsia. Gut 1997;41:513-7.
39. Gillen D, McColl KEL. Does concern about missing malignancy justify endoscopy in uncomplicated dyspepsia in patients aged less than 55? Am J Gastroenterol 1999;94:75-9.
40. Thijs JC, van Zwet AA, Oey HB. Efficacy and side effects of a triple drug regimen for the eradication of Helicobacter pylori. Scand J Gastroenterol 1993;28:934-8.
41. Thijs JC, van Zwet AA, Moolenaar W, Wolfhagen MJ, ten Bokkel HJ. Triple therapy vs. amoxicillin plus omeprazole for treatment of Helicobacter pylori infection: a multicenter, prospective, randomized, controlled study of efficacy and side effects. Am J Gastroenterol 1996;91:93-7.
42. De Boer WA, Tytgat GN. The best therapy for Helicobacter pylori infection: should efficacy or side-effect profile determine our choice? Scand J Gastroenterol 1995;30:401-7.
43. Van der Wouden EJ, Thijs JC, van Zwet AA, Sluiter WJ, Kleibeuker JH. The influence of in vitro nitroimidazole resistance on the efficacy of nitromidazole containing anti-Helicobacter pylori regimens: a meta-analysis. Am J Gastroenterol 1999;94:1751-9.
44. Houben MH, van der Beek D, Hensen EF, Craen AJ, Rauws EA, Tytgat GN. A systematic review of Helicobacter pylori eradication therapy - the impact of antimicrobial resistance on eradication rates. Aliment Pharmacol Ther 1999;13:1047-55.
45. Megraud F. Epidemiology and mechanism of antibiotic resistance in Helicobacter pylori. Gastroenterology 1998;115:1278-82.
46. Arents NLA, van Zwet AA, Thijs JC, Degener JE, Kleibeuker JH. A six-year surveillance of Helicobacter pylori resistance in a large study population in The Netherlands (n = 5946): prevalence of clarithromycin resistance increases, while metronidazole resistance does not increase. Gastroenterology 2001;120:A229.
47. De Boer WA. How to achieve a near 100% cure rate for H. pylori infection in peptic ulcer patients. A personal viewpoint. J Clin Gastroenterol 1996;22:313-6.
48. Labenz J, Blum AL, Bayerdorffer E, Meining A, Stolte M, Borsch G. Curing Helicobacter pylori infection in patients with duodenal ulcer may provoke reflux esophagitis. Gastroenterology 1997;112:1442-7.
49. Verdu EF, Armstrong D, Idstrom JP, Labenz J, Stolte M, Dorta G, et al. Effect of curing Helicobacter pylori infection on intragastric pH during treatment with omeprazole. Gut 1995;37:743-38.
50. Moayyedi P, Bardhan C, Young L, Dixon MF, Brown L, Axon T. Helicobacter pylori eradication does not exacerbate reflux symptoms in gastroesophageal reflux disease. Gastroenterology 2001;121:1120-6.
51. Thijs JC, van Zwet AA, Thijs WJ, Oey HB, Karrenbeld A, Stellaard F, et al. Diagnostic tests for Helicobacter pylori: a prospective evaluation of their accuracy, without selecting a single test as the gold standard. Am J Gastroenterol 1996;91:2125-9.
52. Arents NLA, van Zwet AA, Thijs JC, de Jong A, Oudkerk-Pool M, Kleibeuker JH. The accuracy of the Helicobacter pylori antigen stool test in diagnosisng H. pylori in treated and untreated patients. Eur J Gastroenterol Hepatol 2001;13:383-6.
53. Moayyedi P, Axon AT. The usefulness of the likelihood ratio in the diagnosis of dyspepsia and gastroesophageal reflux disease. Am J Gastroenterol 1999;94:3122-5.
54. Graham DY, Lew GM, Malaty HM, Evans DG, Evans DJ, Klain PD, et al. Factors influencing the eradication of Helicobacter pylori with triple therapy. Gastroenterology 1992;102:493-6.
55. Van der Wouden EJ, Thijs JC, van Zwet AA, Oey HB, Kleibeuker JH. Reliability of biopsy based diagnostic tests for Helicobacter pylori after treatment aimed at its eradication. Eur J Gastroenterol Hepatol 1999;11:1255-8.
56. Peterson WL, Fendrick M, Cave DR, Peura DA, Garabedian-Ruffalo SM, Laine L. Helicobacter pylori-related disease: guidelines for testing and treatment. Arch Intern Med 2000;160:1285-91.
57. Griffin SM, Raimes SA. Proton pump inhibitors may mask early gastric cancer. Dyspeptic patients over 45 should undergo endoscopy before these drugs are started. Br Med J 1998;317:1606-7.
58. Unge P, Jonsson B, Stalhammar NO. The cost effectiveness of Helicobacter pylori eradication versus maintenance and episodic treatment in duodenal ulcer patients in Sweden. Pharmacoeconomics 1995;8:410-27.
59. Kuipers EJ, Lundell L, Klinkenberg-Knol EC, Hanu N, Festen HP, Liedman B, Lamers CB, Jansen JB, Dalenback J, Shel P, Nelis GF, Meuwissen S. Atrophic gastritis and Helicobacter pylori infection in patients with reflux esophagitis treated with omeprazole or fundoplication. N Engl J Med 1996;334:1018-1022.
60. Klinkenberg-Knol EC, Nelis F, Dent J, Snel P, Mitchell B, Prichard P, et al. Long-term omeprazole treatment in resistant gastroesophageal reflux disease: efficacy, safety, and influence on gastric mucosa. Gastroenterology 2000;118:61-9.
61. Winters C, Jr, Spurling TJ, Chobanian SJ, Curtis DJ, Esposito RL, Hacker JF 3rd, et al. Barrett's esophagus. A prevalent, occult complication of gastroesophaseal reflux disease. Gastroenterology 1987;92:118-24.
62. Shaheen NJ, Crosby MA, Bozymski EM, Sandler RS. Is there publication bias in the reporting of cancer risk in Barrett's esophagus? Gastroenterology 2000;119:333-8.
63. Spiegel BMR, Vakil NB, Ofman JJ. Dyspepsia management strategies: a decision analysis of competing strategies. Gastroenterology 2002;122:1270-85.
64. El-Seraq HB, Sonnenberg A. Opposing time trends of peptic ulcer and reflux disease. Gut 1997;43:327-33.
65. Blaser MJ. Helicobacter pylori and gastric diseases. Br Med J 1998;316:1507-10.